Drew Weissman's decades of research helped pave the way for mRNA Covid-19 vaccines, but the scientist isn't resting on his laurels. The University of Pennsylvania immunologist, who on Thursday shared the $3 million 2022 Breakthrough Prize in Life Sciences with his longtime collaborator Katalin Kariko, is now spearheading efforts to design a new vaccine against all coronaviruses. The Silicon Valley-backed award honors major discoveries with the highest cash amounts in science.
Weissman and Karikó are honored for engineering modified RNA technology which enabled rapid development of effective COVID-19 vaccines It was a scientific discovery 16 years ago that paved the way for creation of lifesaving vaccines when the COVID-19 pandemic spread across the globe in 2020. Now, the two Penn Medicine researchers behind the findings are again being recognized for their innovative and monumental work, which has ushered in a new era of vaccine technology. Drew
by Steve Graff Thanks to researchers in different fields who put in nearly two decades of past work on mRNA vaccine technology, people around the world are being immunized today from COVID-19 — and hopefully leading us out of this pandemic. Now, because of the increased focus on this versatile technology and that foundation of research, mRNA vaccines for other diseases have an even greater chance of making it to patients. “The whole platform is very, very flexible,” said Norb
Drew Weissman, MD, PhD, a professor of Infectious Diseases and an mRNA researcher, was honored by “Face the Nation” on CBS News for his groundbreaking work with colleague Katalin Kariko, PhD, an adjunct associate professor, that paved the way for COVID-19 mRNA vaccines. The pair's research and “life’s work” were presented as part of the “winding chain of effort...which has led to 146 million Americans being vaccinated” against COVID-19, the show said. #pennmedicine #mRNA #Cov
By Binayak Dasgupta, Hindustan Times The earliest couple of coronavirus vaccines the world had access to were by Pfizer-BioNTech and Moderna. They have high efficacy rates, and produce some of the strongest immune responses among all Covid-19 vaccines. Common among the two is also their platform – modified mRNA coated in a lipid nano-particle. This technology is the result of research by two scientists, Drew Weissman and Katalin Kariko. In a video interview with Hindustan Tim